Journal
NATURE COMMUNICATIONS
Volume 9, Issue -, Pages -Publisher
NATURE PORTFOLIO
DOI: 10.1038/s41467-018-02851-7
Keywords
-
Categories
Funding
- SINF
- MDACC grant
- NIH Skin Cancer SPORE [P50 CA 093459]
- NCI [P50 CA140388]
- NIH Clinical Research Loan Repayment Program
- National Institutes of Health (NIH/NCATS) [UH3TR00943]
- NIH/NCI [R01-CA182905]
- UT MD Anderson Cancer Center SPORE in Melanoma grant from NIH/NCI [P50 CA093459]
- AIM at Melanoma Foundation
- Miriam Mulva research fund
- Jim Mulva research fund
- CLL Moonshot Flagship project
Ask authors/readers for more resources
Previously we have reported that metastatic melanoma cell lines and tumor specimens have reduced expression of ADAR1 and consequently are impaired in their ability to perform A-to-I microRNA (miRNA) editing. The effects of A-to-I miRNAs editing on melanoma growth and metastasis are yet to be determined. Here we report that miR-378a-3p is undergoing A-to-I editing only in the non-metastatic but not in metastatic melanoma cells. The function of the edited form is different from its wild-type counterpart. The edited form of miR-378a-3p preferentially binds to the 3'-UTR of the PARVA oncogene and inhibits its expression, thus preventing the progression of melanoma towards the malignant phenotype. Indeed, edited miR-378a-3p but not its WT form inhibits melanoma metastasis in vivo. These results further emphasize the role of RNA editing in melanoma progression.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available